Celltrion reports first preclinical data for four-target obesity drug CT-G32/SCO-940

Celltrion said on 4 November that it presented the first preclinical results for CT-G32/SCO-940, a quadruple-action obesity candidate, at TIDES Europe in Amsterdam. The conference ran from 3 to 5 November. The molecule binds four hormone pathways in one: GLP-1, GIP, glucagon and amylin. Celltrion co-develops it with Japan's SCOHIA PHARMA. Based on publicly disclosed development status, the company calls it the world's first obesity treatment to combine all four pathways in a single candidate.

No human has taken CT-G32/SCO-940. The efficacy claims presented so far rest on preclinical work: cell assays and studies in diet-induced obese rodents.

What the preclinical data show

The package covered receptor-level cell activity and body weight, body composition and blood insulin in diet-induced obese rodents. Celltrion says the candidate produced greater weight loss than Eli Lilly's retatrutide at the same dose. The animals lost a smaller share of lean mass, including muscle and bone, than with retatrutide during that weight reduction. Blood insulin levels also fell, which Celltrion reads as a possible route into metabolic disease beyond obesity. Primate pharmacokinetic data showed sustained exposure, which the company says supports a once-weekly subcutaneous formulation.

The disclosed results give no effect sizes for weight loss or lean mass, only the direction of the comparison. That limits what the retatrutide claim can bear: four pathways against three is a count of targets, not a measured result.

Preclinical animal data do not guarantee efficacy or safety in humans. Quadruple action could also bring tolerability problems such as gastrointestinal side effects, which only clinical trials can settle. "We have confirmed in nonclinical studies the potential for differentiation beyond existing dual- and triple-action agents," a Celltrion official said. "We will push ahead with clinical entry without disruption and develop it into a next-generation treatment that encompasses not only weight loss but also improvements in body composition and metabolism."

Muscle preservation is the claim Celltrion leans on hardest. Losing lean mass along with fat is a common complaint about obesity drugs. Celltrion argues that losing a smaller share of it is a difference worth developing for.

The field it enters

Obesity is the most contested area in the pharmaceutical industry. Novo Nordisk's semaglutide opened the market, and Eli Lilly's retatrutide, a triple-action agent, is the comparator Celltrion chose. Celltrion frames the unmet need as variable efficacy across patients on existing GLP-1 therapies, plus muscle loss during weight reduction. It says it wants to hit weight loss, body composition and energy-metabolism regulation at once.

What happens next

Celltrion plans to submit an investigational new drug application to the FDA in February 2027. If the review goes smoothly, it aims to dose the first patient in a global Phase 1 trial in the second quarter of that year. The timing matches the "next year" clinical-entry target the company previously presented. The application would open the first human testing of a molecule that Celltrion has so far described only in preclinical terms.

Celltrion's established business is in biosimilars, and it says it aims to apply capabilities built there to new drug development. For investors, the key question is whether the new drug pipeline can add value to an earnings base centered on biosimilars. Development costs are expected to rise once the obesity candidate enters clinical trials.